Georgiamune, a privately held, clinical stage biotechnology company, and Verily, an Alphabet precision health technology company, announced a strategic partnership to advance novel therapeutics for patients with cancer.
The partnership will focus on deploying Verily’s advanced molecular and real-world evidence solutions with the intention to support the development of Georgiamune’s therapeutic candidates through the discovery of predictive and outcome biomarkers. The two companies will also focus on driving more efficient clinical development by incorporating clinical trial data and longitudinal real-world data sources. The collaboration innovates how clinical trials are currently conducted by bringing together different data modalities to identify the patient populations most likely to benefit from Georgiamune’s novel therapy and by providing a more holistic analysis of how participants are responding to the therapy over time.
As a first step, the partners will implement immune mapping with Verily’s Immune Profiler for GIM-122, a first-in-class dual-functioning antibody currently being evaluated for safety, tolerability, and antitumor activity in a first-in-human, phase 1/2 clinical trial in adults with checkpoint refractory or resistant advanced solid tumor malignancies. Georgiamune will utilize Immune Profiler to assess the pharmacodynamic effect of GIM-122 and interrogate the immune response of patients. As part of the partnership, the two companies will also aim to expand into other assets developed by Georgiamune in cancer and other therapeutic areas, including autoimmune diseases.
“This partnership combines Verily’s expertise in developing connected solutions that advance research and care across oncology and autoimmune diseases with Georgiamune’s innovative approach to drug development,” said Amy Abernethy, MD, PhD, President of Product Development and Chief Medical Officer at Verily. “We are proud to work with Georgiamune as they use novel data sources to break new ground in the fight against cancer.”
Immune Profiler is part of Verily Numetric, a suite of precision measurement solutions that enables deeper insights on health and disease to create richer, more diverse datasets that fuel medical research. The collaboration will also employ Verily Viewpoint, a suite of tools and services that power data and evidence generation.
SOURCE: Businesswire